Список литературы

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what 4332 it isn't? BMJ. 1996; 312(7023):71–72. 4333 2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) "Об основах охраны 4334 здоровья граждан в Российской Федерации". 4335 3. Эпидемиологический словарь, 4-е издание. Под редакцией Джона М. Ласта для 4336 Международной эпидемиологической ассоциации. Москва, 2009, стр. 316. 4337 4. Федеральное агентство по техническому регулированию и метрологии. Клиническая 4338 практика. Москва, 2005. 4339 5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об обращении 4340 лекарственных средств». 4341 6. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and 4342 treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of 4343 Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European 4344 Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital 4345 Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart 4346 J. 2016; 37(1): 67–119. 4347 7. Малая медицинская энциклопедия. – М.: Медицинская энциклопедия. 1991–96гг. 4348 [Электронный ресурс]. http://dic.academic.ru/dic.nsf/ enc_medicine/28878/Синдром. 4349 8. Андреева Н. С., Реброва О. Ю., Зорин Н. А., др. Системы оценки достоверности 4350 научных доказательств и убедительности рекомендаций: сравнительная характеристика и 4351 перспективы унификации. Медицинские технологии. Оценка и выбор. 2012; 4: 10–24. 4352 9. Hoeper MM, Apitz C, Grünig E, et al. Targeted therapy of pulmonary arterial hypertension: 4353 Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 4354 272S:37–45. 4355 10. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of 4356 pulmonary arterial hypertension. Eur Respir J. 2019; 53(1): pii:1801889. 4357 11. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and 4358 updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53:1801913. 4359 12. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 4360 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed 4361 by the task force for the diagnosis and treatment of pulmonary hypertension of the European 4362 Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the 4363 International Society for Heart and Lung Transplantation (ISHLT) and the European Reference 4364 Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022; 43(38): 3618–3731. 4365 13. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and 4366 exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34(4):888–894. 4367 14. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical 4368 outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir 4369 Med. 2020; 8:873–884. 4370 15. Авдеев С.Н., Барбараш О.Л., Баутин А.Е., др. Легочная гипертензия, в том 4371 числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 4372 2020. Российский кардиологический журнал. 2021; 26(12):4683. 4373 16. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские клинические 4374 рекомендации по диагностике и лечению легочной гипертензии (2019). Евразийский 4375 Кардиологический Журнал. 2020; 1:78-122. 4376 17. Chazova IE, Martynyuk TV, Valieva ZS, et al. Clinical and Instrumental 4377 Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension 4378 according to the Russian National Registry. BioMed Research International. 2020: 6836973. 4379 https://doi.org/10.1155/2020/6836973, PMID: 32626754 114 4380 18. Frost A, Badesch D, Simon JR, et al. Diagnosis of pulmonary hypertension. Eur 4381 Respir J. 2019; 53:1801904. 4382 19. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with 4383 preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation 4384 from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur 4385 Heart J.2019; 40: 3297–3317. 4386 20. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. 4387 Lancet Respir Med. 2016; 4: 306–322. 4388 21. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension 4389 and chronic thromboembolic pulmonary hypertension: identification of the most accurate 4390 estimates from a systematic literature review. Pulm Circ.2021; 11: 2045894020977300. 4391 22. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national 4392 prospective study.Ann Intern Med. 1987; 107(2). 216–223. 4393 23. Montani D, Girerd B, Jais X, et al. Screening for pulmonary arterial hypertension 4394 in adults carrying a BMPR2 mutation. Eur Respir J. 2020; 58: 2004229. 4395 24. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, 4396 familial, and anorexigen-associated pulmonary arterial hypertension in the modern management 4397 era. Circulation. 2010; 122 (2):156–163; 4398 25. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: 4399 baseline characteristics from the REVEAL Registry. Chest. 2010; 137 (2):376–387. 4400 26. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with 4401 idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 4402 2013; 168(2):871–880. 4403 27. Certain MC, Chaumais MC, Jais X, et al. Characteristics and long-term outcomes 4404 of pulmonary venoocclusive disease induced by mitomycin C. Chest. 2021;159:1197–1207. 4405 28. Cornet L, Khouri C, Roustit M, et al. Pulmonary arterial hypertension associated 4406 with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J. 2019; 4407 53:1802472. 4408 29. Weatherald J, Bondeelle L, Chaumais MC, et al. Pulmonary complications of Bcr4409 Abl tyrosine kinase inhibitors. Eur Respir J. 2020; 56: 2000279. 4410 30. Chen SC, Dastamani A, Pintus D, et al. Diazoxide-induced pulmonary hypertension 4411 in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the UK. Clin 4412 Endocrinol (Oxf). 2019; 91: 770–775. 4413 31. Rosenkranz S, Lang IM, Blindt R, et al. Pulmonary hypertension associated with 4414 left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Int J 4415 Cardiol. 2018; 272S: 53–62. 4416 32. Global Burden of Disease Study Collaborators. Global, regional, and national 4417 incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and 4418 injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 4419 2013. Lancet. 2015; 386: 743–800. 4420 33. Mehra P, Mehta V, Sukhija R, et al. Pulmonary hypertension in left heart disease. 4421 Arch Med Sci. 2019; 15(1): 262–273. 4422 34. Tichelbacker T, Dumitrescu D, Gerhardt F, et al. Pulmonary hypertension and 4423 valvular heart disease. Herz. 2019; 44: 491–501. 4424 35. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results 4425 from the ASPIRE registry. Eur Respir J. 2013; 41: 1292–1301. 4426 36. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung 4427 disease and hypoxia. Eur Respir J 2019; 53:1801914. 4428 37. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J. 2019; 53 4429 (6):1900985. 4430 38. Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic 4431 thromboembolic pulmonary hypertension. Eur Respir J. 2021; 57(6): 2002828. 115 4432 39. Kramm T, Wilkens H, Fuge J, et al. Incidence and characteristics of chronic 4433 thromboembolic pulmonary hypertension in Germany. Clinical research in cardiology: official 4434 journal of the German Cardiac Society. 2018;1–6 () doi:10.1007/s00392-018-1215-5. 4435 40. Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of 4436 sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017; 50:1700465. 4437 41. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of 4438 pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019; 53(1). pii: 4439 1801887. 4440 42. Olschewski A, Berghausen EM, Eichstaedt CA, et al. Pathobiology, pathology and 4441 genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. Int J 4442 Cardiol. 2018; 272S:4–10. 4443 43. Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic 4444 thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26 (143): pii: 160112. 4445 44. Чазова И.Е., Мартынюк Т.В., Валиева З.С., др. Евразийские рекомендации по 4446 диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). 4447 Евразийский Кардиологический Журнал. 2021;1:6-43. 4448 45. Бокерия Л.А., Горбачевский С.В., Шмальц А.А. Легочная артериальная 4449 гипертензия, ассоциированная с врожденными пороками сердца у взрослых (клиническая 4450 рекомендация). Грудная и сердечно-сосудистая хирургия. 2017; 59(2): 135-47. 4451 46. Чазова И.Е., Валиева З.С., Наконечников С.Н., др. Особенности клинико4452 функционального и гемодинамического профиля, лекарственной терапии и оценка 4453 прогноза у пациентов с неоперабельной хронической тромбоэмболической и 4454 идиопатической легочной гипертензией по данным Российского регистра. 4455 Терапевтический архив. 2019; 91(9): 77-87. 4456 47. Чазова И. Е., Авдеев С. Н., Царева Н. А., др. Клинические рекомендации по 4457 диагностике и лечению легочной гипертонии.Терапевтический архив. 2014; 9: 4–23. 4458 48. Чазова И.Е., Горбачевский С.В., Мартынюк Т.В. и др. Евразийские 4459 рекомендации по диагностике и лечению легочной гипертензии, ассоциированной с 4460 врожденными пороками сердца у взрослых (2021). Евразийский кардиологический журнал. 4461 2022; 2: 6–70. 4462 49. Мартынюк Т.В. Легочная гипертензия: диагностика и лечение. Москва: ООО 4463 «Медицинское информационное агентство», 2018. 304 с. 4464 50. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality 4465 in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818. 4466 51. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная 4467 гипертензия в России: анализ шестилетнего наблюдения по данным Национального 4468 регистра. Терапевтический архив. 2019; 91(1): 10–31. 4469 52. Хроническая тромбоэмболическая легочная гипертензия : Руководство для 4470 врачей / Под ред. Т.В. Мартынюк, акад. РАН И.Е. Чазовой. — Москва : ООО «Медицинское 4471 информационное агентство», 2023. 416 с. 4472 53. Алокова Ф.Х., Блинова Е.В., Сахнова Т.А., др. Изменения 4473 электрокардиограммы в 12 отведениях у больных с идиопатической легочной 4474 гипертензией. Медицинский алфавит. 2018; 36(4): 29−35. 4475 54. Bonderman D, Wexberg P, Martischnig AM, et al. A noninvasive algorithm to 4476 exclude pre-capillary pulmonary hypertension. Eur Respir J. 2011; 37:1096–1103. 4477 55. Rich JD, Thenappan T, Freed B, et al. QTc prolongation is associated with impaired 4478 right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol 2013; 4479 167:669–676. 4480 56. Mercurio V, Peloquin G, Bourji KI, et al. Pulmonary arterial hypertension and atrial 4481 arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018; 4482 8(2):2045894018769874. 116 4483 57. Klok FA, Surie S, Kempf T, et al. A simple non-invasive diagnostic algorithm for 4484 ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary 4485 embolism. Thromb Res 2011;128:21–26. 4486 58. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function 4487 tests. Eur Respir J. 2005; 26: 948–968. 4488 59. Wright LM, Dwyer N, Celermajer D, et al. Follow-Up of Pulmonary Hypertension 4489 With Echocardiography. JACC Cardiovasc Imaging. 2016; 9(6):733-746. 4490 60. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic 4491 assessment of the right heart in adults: a report from the American Society of Echocardiography 4492 endorsed by the European Association of Echocardiography, a registered branch of the European 4493 Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 4494 2010; 23: 685–713. 4495 61. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber 4496 quantification by echocardiography in adults:an update from the American Society of 4497 Echocardiography and the European Association of Cardiovascular Imaging. EurHeart J 4498 Cardiovasc Imaging. 2015; 16: 233–270. 4499 62. Белевская А.А., Дадачева З.Х., Саидова М.А., др. Возможности 4500 эхокардиографии в диагностике легочной гипертензии и оценке ремоделирования сердца. 4501 Лечебное дело. 2015; 1:111–121. 4502 63. Неклюдова Г.В., Науменко Ж.К. Эхокардиография при диагностике легочной 4503 гипертензии. Практическая пульмонология. 2015; 2: 48 – 56. 4504 64. Казымлы А.В., Рыжков А.В., Симакова М.А.,и др. Значение двухмерной 4505 эхокардиографии в оценке степени тяжести пациентов с легочной гипертензией 4506 Кардиология. 2016; 56(1):25-30. 4507 65. Balakrishnan B, Owens B, Hayes R, et al. A Systematic Review of 4508 Echocardiographic Parameters for the Screening of Pulmonary Hypertension: What Are the Odds? 4509 Cureus 14(12): e32185. 4510 66. D'Alto M, Di Maio M, Romeo E, et al. Echocardiographic probability of pulmonary 4511 hypertension: a validation study. Eur Respir J. 2022; 60: 2102548. 4512 67. Magnino C, Omede P, Avenatti E, et al. Inaccuracy of right atrial pressure estimates 4513 through inferior vena cava indices. Am J Cardiol 2017; 120(9): 1667–1673. 4514 68. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic 4515 estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for 4516 clinical practice. Chest. 2011;139(5): 988-993. 4517 69. Finkelhor RS, Lewis SA, Pillai D. Limitations and strengths of doppler/echo 4518 pulmonary artery systolic pressure-right heart catheterization correlations: a systematic literature 4519 review. Echocardiography. 2015;32(1): 10-18. 4520 70. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary 4521 hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J 4522 Am Coll Cardiol. 1985; 6(2):359-365. 4523 71. Greiner S, Jud A, Aurich M, et al. Reliability of noninvasive assessment of systolic 4524 pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: 4525 analysis in a large patient population. J Am Heart Assoc. 2014; 3(4): e001103. 4526 72. Ni JR, Yan PJ, Liu SD, et al. Diagnostic accuracy of transthoracic echocardiography 4527 for pulmonary hypertension: a systematic review and meta-analysis. BMJ Open. 2019; 9(12): 4528 e033084. 4529 73. Gall H, Yogeswaran A, Fuge J, et al. Validity of echocardiographic tricuspid 4530 regurgitation gradient to screen for new definition of pulmonary hypertension. E Clinical 4531 Medicine. 2021; 34: 100822. 4532 74. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a 4533 noninvasive technique for evaluation of left ventricular relaxation and estimation of filling 4534 pressures. J Am Coll Cardiol. 1997; 30(6):1527 - 33. 117 4535 75. Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic Screening for 4536 Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week. J Am 4537 Coll Cardiol. 2018;72(22):2778-2788. 4538 76. Farmakis IT, Demerouti E, Karyofyllis P et al. Echocardiography in Pulmonary 4539 Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility? J Clin Med. 4540 2021;10(13):2826. 4541 77. Bajc M, Schümichen, C., Grüning, T. et al. EANM guideline for 4542 ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of 4543 pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019; 46: 2429–2451. 4544 78. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more 4545 sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a 4546 treatable cause of pulmonary hypertension. J Nucl Med 2007; 48:680–684. 4547 79. Архипова О.А., Мартынюк Т.В., Самойленко Л.Е., др. Перфузионная 4548 сцинтиграфия легких у больных с легочной гипертенззией различной этиологии. 4549 Евразийский кардиологический журнал. 2015; 4: 21-25. 4550 80. Johns CS, Swift AJ, Rajaram S, et al. Lung perfusion: MRI vs. SPECT for screening 4551 in suspected chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging. 2017; 46: 4552 1693–1697. 4553 81. Masy M, Giordano J, Petyt, G, et al. Dual-energy CT (DECT) lung perfusion in 4554 pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing chronic 4555 thromboembolic pulmonary hypertension (CTEPH). Eur Radiol. 2018; 28: 5100–5110. 4556 82. Dissaux, B, Le Floch, PY, Robin, P, et al. Pulmonary perfusion by iodine 4557 subtraction maps CT angiography in acute pulmonary embolism: comparison with pulmonary 4558 perfusion SPECT (PASEP trial). Eur Radiol 2020; 30: 4857–4864.. 4559 83. Czerner CP, Schoenfeld C, Cebotari S, et al. Perioperative CTEPH patient 4560 monitoring with 2D phase-contrast MRI reflects clinical, cardiac and pulmonary perfusion changes 4561 after pulmonary endarterectomy. PLOS ONE. 2020; 15(9): e023817б. 4562 84. Remy-Jardin M, Ryerson CJ, Schiebler ML, et al. Imaging of pulmonary 4563 hypertension in adults: a position paper from the Fleischner Society. Eur Respir J. 4564 2021;57:2004455. 4565 85. Swift AJ, Dwivedi K, Johns C, et al. Diagnostic accuracy of CT pulmonary 4566 angiography in suspected pulmonary hypertension. Eur Radiol. 2020;30:4918–4929. 4567 86. Dong C, Zhou M, Liu D, et al. Diagnostic accuracy of computed tomography for 4568 chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. PLoS 4569 One. 2015;10: e0126985. 4570 87. Rajaram S, Swift AJ, Capener D, et al. Diagnostic accuracy of contrast-enhanced 4571 MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography 4572 in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2012; 22:310–317. 4573 88. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, et al. Usefulness of standard 4574 computed tomography pulmonary angiography performed for acute pulmonary embolism for 4575 identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. 4576 J Heart Lung Transplant. 2019;38:731–738. 4577 89. Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic 4578 pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary 4579 embolism. Thromb Haemost. 2014;112:598–605. 4580 90. Tamura M, Yamada Y, Kawakami T, et al. Diagnostic accuracy of lung subtraction 4581 iodine mapping CT for the evaluation of pulmonary perfusion in patients with chronic 4582 thromboembolic pulmonary hypertension: correlation with perfusion SPECT/CT. Int J Cardiol. 4583 2017;243:538–543. 4584 91. Masy M, Giordano J, Petyt G, Hossein-Foucher C, et al. Dual-energy CT (DECT) 4585 lung perfusion in pulmonary hypertension: concordance rate with V/Q scintigraphy in diagnosing 4586 chronic thromboembolic pulmonary hypertension (CTEPH). Eur Radiol. 2018;28:5100–5110. 118 4587 92. Веселова Т.Н., Демченкова А.Ю., Ен М.Ю., др. Оценка перфузии легких у 4588 больных хронической тромбоэмболической легочной гипертензией методами 4589 компьютерной томографии и сцинтиграфии. REJR. 2022; 12(2):94-103. 4590 93. Montani D, Girerd B, Jais X, et al. Clinical phenotypes and outcomes of heritable 4591 and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med. 4592 2017;5:125–134. 4593 94. Schiebler ML, Bhalla S, Runo J, et al. Magnetic resonance and computed 4594 tomography imaging of the structural and functional changes of pulmonary arterial hypertension. 4595 J Thorac Imaging. 2013; 28(3): 178–193. 4596 95. de Siqueira MEM, Pozo E, Fernandes VR, et al. Characterization and clinical 4597 significance of right ventricular mechanics in pulmonary hypertension evaluated with 4598 cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson. 2016;18(1): 39. 4599 96. Amzulescu MS, De Craene M, Langet H, et al. Myocardial strain imaging: review 4600 of general principles, validation, and sources of discrepancies. Eur Heart J Cardiovasc Imaging. 4601 2019; 20(6):605–619 4602 97. Ray JC, Burger C, Mergo P, et al. Pulmonary arterial stiffness assessed by 4603 cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. 4604 Int J Cardiovasc Imaging. 2019; 35(10):1881–1892. 4605 98. Ohno Y, Yoshikawa T, Kishida Y, et al. Unenhanced and contrast-enhanced MR 4606 angiography and perfusion imaging for suspected pulmonary thromboembolism. Am J 4607 Roentgenol. 2017; 208 (3):517-530 4608 99. Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular 4609 magnetic resonance imaging of right ventricular morphology and function in the assessment of 4610 suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson 4611 2012; 14:40–50. 4612 100. Swift AJ, Rajaram S, Hurdman J. et al. Noninvasive estimation of PA pressure, 4613 flow, and resistance with CMR imaging: derivation and prospective validation study from the 4614 ASPIRE registry. JACC Cardiovasc Imaging 2013; 6: 1036–1047. 4615 101. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. 4616 SwissMed Wkly. 2003; 133:163–169. 4617 102. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic 4618 consequences of pulmonary hypertension and right-sided heart failure. Circulation. 2020;141:678– 4619 693. 4620 103. Шмальц А.А. Динамика дистанции шестиминутной ходьбы как показатель 4621 эффективности специфических легочных вазодилататоров. Рациональная Фармакотерапия 4622 в Кардиологии. 2022; 18(3):342-349. 4623 104. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance 4624 predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 4625 randomized trials. J Am Coll Cardiol. 2012; 60(13): 1192–1201. 4626 105. Таран И.Н., Валиева З.С., Мартынюк Т.В., др. Вклад спировелоэргометрии в 4627 диагностический алгоритм обследования больных с легочной артериальной гипертензией. 4628 Медицинский алфавит. Больница (кардиология). 2016; 3: 19-23. 4629 106. Казымлы А.В., Березина А.В., Рыжков А.В., др. Кардиопульмональное 4630 тестирование как метод оценки степени тяжести пациентов с прекапиллярной легочной 4631 гипертензией. Кардиология. 2014; 54(12): 22–28. 4632 107. Dumitrescu D, Nagel C, Kovacs G, et al. Cardiopulmonary exercise testing for 4633 detecting pulmonary arterial hypertension in systemic sclerosis. Heart 2017; 103:774–782. 4634 108. Boerrigter BG, Bogaard HJ, Trip P, et al. Ventilatory and cardiocirculatory exercise 4635 profiles in COPD: the role of pulmonary hypertension. Chest. 2012; 142:1166–1174. 4636 109. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart 4637 catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am 4638 Coll Cardiol. 2006;48:2546–2552. 119 4639 110. D’Alto M, Dimopoulos K, Coghlan JG, et al. Right heart catheterization for the 4640 diagnosis of pulmonary hypertension: controversies and practical issues. Heart Fail Clin 4641 2018;14:467–477. 4642 111. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right 4643 heart catheterisation. Eur Respir J. 2013;42:1586–1594. 4644 112. Куропий Т.С., Данилов Н.М., Матчин Ю.Г. Сосудистые доступы к правым 4645 отделам сердца и легочным артериям: современное состояние вопроса. Кардиологический 4646 вестник. 2022;17(3):23‑28. 4647 113. Шмальц А.А., Мартынюк Т.В., Наконечников С.Н. Расчет гемодинамики 4648 методом Фика при легочной гипертензии, ассоциированной с врожденными пороками 4649 сердца. Евразийский кардиологический журнал. 2022;(2):96-102. 4650 114. Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated Fick cardiac 4651 output measurement in clinical practice: an analysis of mortality from the Veterans Affairs Clinical 4652 Assessment, Reporting, and Tracking (VA CART) Program and Vanderbilt University. JAMA 4653 Cardiol. 2017; 2:1090–1099. 4654 115. Viray MC, Bonno EL, Gabrielle ND, et al. Role of pulmonary artery wedge 4655 pressure saturation during right heart catheterization: a prospective study. Circ Heart Fail. 4656 2020;13:e007981. 4657 116. Vachiery JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left 4658 heart disease. Eur Respir J. 2019; 53: 1801897. 4659 117. Kubiak GM, Ciarka A, Biniecka M, et al.. Right heart catheterization – background, 4660 physiological basics, and clinical implications. J Clin Med 2019; 8: 1331. 4661 118. Kaemmerer H, Apitz C, Brockmeier K, et al. Pulmonary hypertension in adults 4662 with congenital heart disease: Updated recommendations from the Cologne Consensus Conference 4663 2018. Int J Cardiol. 2018; 272S:79-88. 4664 119. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the 4665 Management of Adults With Congenital Heart Disease: A Report of the American College of 4666 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 4667 2019; 139 (14):e698-e800. 4668 120. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel 4669 blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111. 4670 121. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute 4671 hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary 4672 hypertension. German PPH study group. J Am Coll Cardiol. 2000; 35:176–182. 4673 122. Шмальц А.А., Горбачевский С.В., Мартынюк Т.В., Наконечников С.Н. Тест 4674 на вазореактивность при лёгочной гипертензии, ассоциированной с врождёнными 4675 пороками сердца. Евразийский кардиологический журнал. 2022; 3:58-64, 4676 123. Wilkens Н, Konstantinides S, Lang IM, et al. Chronic thromboembolic pulmonary 4677 hypertension (CTEPH): Updated recommendations from the Cologne Consensus Conference 4678 2018. Int. J. Cardiol. 2018; 272: 69-78. 4679 124. Юрпольская Л.А., Шмальц А.А. Рентгенография, рентгеновская 4680 компьютерная и магнитно-резонансная томография при легочной гипертензии, 4681 ассоциированной с врожденными пороками сердца. Детские болезни сердца и сосудов. 4682 2021; 18 (2): 83-93. 4683 125. Легочная гипертензия. Под редакцией С. Н. Авдеева. Москва. ГЭОТАР4684 Медиа. 2019, 608стр. 4685 126. Jilwan FN, Escourrou P, Garcia G, et al. High occurrence of hypoxemic sleep 4686 respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2013; 4687 143:47–55. 4688 127. Mancuso L, Scordato F, Pieri M, et al. Management of portopulmonary 4689 hypertension: new perspectives. World J Gastroenterol. 2013;19: 8252–8257. 120 4690 128. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related 4691 pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care 4692 Med. 2008;177:108–113. 4693 129. Волков А.В., Мартынюк Т.В. Легочная артериальная гипертензия при 4694 системных заболеваниях соединительной ткани: современное состояние проблемы. 4695 Научно-практическая ревматология. 2018; 56(4):474−486. 4696 130. Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial 4697 hypertension in systemic sclerosis. Eur Respir Rev. 2019;28:190023. 4698 131. Morrisroe K, Huq M, Stevens W, et al. Risk factors for development of pulmonary 4699 arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter 4700 cohort study. BMC Pulm Med. 2016;16:134. 4701 132. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary 4702 arterial hypertension in systemic sclerosis:the DETECT study. Ann Rheum Dis. 2014;73:1340– 4703 1349 4704 133. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial 4705 hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis 4706 Rheum. 2005;52:3792–3800. 4707 134. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial 4708 hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term 4709 survival. Arthritis Rheum. 2011;63:3522–3530. 4710 135. Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary 4711 arterial hypertension. Eur Respir J. 2019;53:1801899. 4712 136. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial 4713 hypertension. Eur Heart J Suppl. 2019; 21:K9–K20. 4714 137. Boon G, Ende-Verhaar YM, Bavalia R, et al. Non-invasive early exclusion of 4715 chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II 4716 study. Thorax 2021;76:1002–1009. 4717 138. Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk 4718 stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur 4719 Heart J. 2018;39:4175–4181. 4720 139. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: 4721 prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur 4722 Respir J. 2017; 50:1700740. 4723 140. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline 4724 implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50:1700889. 4725 141. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged 4726 version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with 4727 pulmonary arterial hypertension. Chest. 2021;159: 337–346. 4728 142. Zelniker TA, Huscher D, Vonk-Noordegraaf A, et al. The 6MWT as a prognostic 4729 tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 4730 2018;107(6):460-70. 4731 143. Provencher S, Chemla D, Herve P, et al. Heart rate responses during the 6-minute 4732 walk test in pulmonary arterial hypertension. Eur Respir J. 2006;27:114–120 4733 144. Khirfan G, Naal T, Abuhalimeh B, et al. Hypoxemia in patients with idiopathic or 4734 heritable pulmonary arterial hypertension. PLoS One. 2018;13:e0191869. 4735 145. Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial 4736 hypertension: insights from the GRIPHON study. J Heart Lung Transpl. 2020;39:300–309. 4737 146. Nickel N, Golpon H, Greer M, et. al. The prognostic impact of follow-up 4738 assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 4739 39:589–596. 121 4740 147. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary 4741 arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015; 34(3): 4742 362–368. 4743 148. Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic 4744 relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 4745 2013; 8(9):e72013. 4746 149. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic 4747 peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest. 2007; 4748 131(2):402–409. 4749 150. Morris N.R., Kermeen F.D., Holland A.E. Exercise-based rehabilitation programs 4750 for pulmonary hypertension. Cochrane Database of Systematic Reviews. 2017;1(1):CD011285. 4751 doi:10.1002/14651858.cd011285.pub2. 4752 151. Chia KSW., Wong PKK., Faux SG. et al. The benefit of exercise training in 4753 pulmonary hypertension: a clinical review. Intern Med J 2017; 47(4): 361–369. 4754 152. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular 4755 assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 4756 2022;43(39):3826-3924. 4757 153. Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric 4758 surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013;41:1302– 4759 1307. 4760 154. Thangamathesvaran, L., Armenia, S. J., Merchant, A. M. The effect of pulmonary 4761 hypertension on inpatient outcomes of laparoscopic procedures. Updates in Surgery. 2018 4762 doi:10.1007/s13304-018-0556-y. 4763 155. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487– 4764 497. 4765 156. Чазова И.Е, Мартынюк Т.В, Валиева З.С, др. Оценка бремени хронической 4766 тромбоэмболической легочной гипертензии в Российской Федерации. Терапевтический 4767 архив. 2018; 9: 101-109. 4768 157. Schneider SR, Mayer LC, Lichtblau M, et al. Effect of a day-trip to altitude (2500 4769 m) on exercise performance in pulmonary hypertension: randomized crossover trial. ERJ Open 4770 Res 2021;7:00314-02021. 4771 158. Groth A, Saxer S, Bader PR, et al. Acute hemodynamic changes by breathing 4772 hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary 4773 hypertension. Int J Cardiol. 2018; 270:262–267 4774 159. Grünig, E, Benjamin, N, Krüger, U, et al. General measures and supportive therapy 4775 for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus 4776 Conference 2018. Int J of Cardiology. 2018. doi:10.1016/j.ijcard.2018.08.085. 4777 160. Грацианская С.Е., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. 4778 Проблемные аспекты применения оральных антикоагулянтов у пациентов с легочной 4779 артериальной гипертензией различного генеза. Евразийский Кардиологический Журнал. 4780 2017; 4:122-132. 4781 161. Гончарова Н. С., Симакова М. А., Моисеева О. М. Антитромботическая 4782 терапия у пациентов с легочной артериальной гипертензией. Артериальная гипертензия. 4783 2019; 25(1):25–33. 4784 162. Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for 4785 patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. 4786 Thromb Res. 2020;196:251–256. 4787 163. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid 4788 retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J 4789 Suppl. 2019;21:K46–K53. 4790 164. Condliffe R, Kiely DG. Critical care management of pulmonary hypertension. BJA 4791 Education. 2017; 17(7): 228–234. 122 4792 165. Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial 4793 hypertension: a potential therapeutic target. Eur Respir J. 2011; 38(6):1453–1460. 4794 166. Olsson KM, Fuge J, Brod T, et al. Oral iron supplementation with ferric maltol in 4795 patients with pulmonary hypertension. Eur Respir J.2020;56:2000616. 4796 167. Howard LSGE, He J, Watson GMJ, et al. Supplementation with iron in pulmonary 4797 arterial hypertension. Two randomized crossover trials. Ann Am Thorac Soc 2021;18:981–988. 4798 168. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in 4799 patients with pulmonary hypertension. Int J Cardiol. 2013; 167:2300–2305. 4800 169. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp 4801 Pharmacol. 2013;218:199–227. 4802 170. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of 4803 pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, 4804 randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. 4805 Circulation. 2008; 117:3010–3019. 4806 171. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial 4807 hypertension. N Engl J Med. 2002;346:896–903. 4808 172. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing 4809 surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–344 4810 173. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary 4811 arterial hypertension. N Engl J Med. 2005;353: 2148–2157. 4812 174. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении 4813 легочной гипертензии: сходства и различия. Пульмонология. 2016; 26 (1): 85–91. 4814 175. Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination 4815 on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011;51:1071–1078. 4816 176. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of 4817 pulmonary hypertension. Expert Opin Investig Drugs. 2011;20:567–576. 4818 177. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of 4819 pulmonary arterial hypertension. N Engl J Med. 2013;369: 330–340. 4820 178. Ghofrani H-A, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in 4821 patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open4822 label, randomized, long-term extension trial. Lancet Respir Med. 2016; 4: 361–371. 4823 179. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am 4824 J Respir Med. 2003;2:123–137. 4825 180. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur 4826 Respir Rev. 2009; 18(111): 29–34. 4827 181. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line 4828 inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 4829 2005; 26: 1895–1902. 4830 182. Мартынюк Т.В. Оценка приверженности пациентов с легочной гипертензией 4831 лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового 4832 неинтервенционного исследования IVENT. Системные гипертензии. 2019;16(2):12-27. 4833 183. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary 4834 arterial hypertension. N Engl J Med. 2015;373:2522–2533. 4835 184. Boucly A, Savale, L, Jaïs, X, et al. Association between Initial Treatment Strategy 4836 and Long-Term Survival in Pulmonary Arterial Hypertension. Am J of Respir and Crit Care Med. 4837 2021; 204(7), 842–854. 4838 185. Kim, N. H., Fisher, M., Poch, D., et al. Long-term outcomes in pulmonary arterial 4839 hypertension by functional class: a meta-analysis of randomized controlled trials and observational 4840 registries. Pulm Circulation. 2020; 10(4): 2045894020935291. 4841 186. Hung CC, Cheng CC, Huang WC, et al. Management of Pulmonary Arterial 4842 Hypertension Patients with World Health Organization Functional Class II. Acta Cardiol Sin. 4843 2020;36(6):583-587. 123 4844 187. Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной 4845 комбинированной специфической терапии легочной артериальной гипертензии в 4846 Российской Федерации. Терапевтический архив. 2020; 92 (12): 80-85. 4847 188. Lang I M, Palazzini, M. The burden of comorbidities in pulmonary arterial 4848 hypertension. Eur Heart J Suppl. 2019; 21(Suppl K): K21–K28. 4849 189. McLaughlin VV, Vachiery, JL, Oudiz, RJ, et al. (AMBITION Study Group). 4850 Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results 4851 from the AMBITION trial. J of Heart and Lung transplantation: the official publication of the 4852 International Society for Heart Transplantation. 2019; 38(12): 1286–1295. 4853 190. Hoeper MM, McLaughlin VV, Barbera JA, et al. Initial combination therapy with 4854 ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a 4855 secondary analysis of the results from the randomized, controlled AMBITION study. Lancet 4856 Respir Med. 2016;4:894–901. 4857 191. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with 4858 Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. 4859 Circulation 2006;114:48–54. 4860 192. Чазова И.Е., Мартынкю Т.В. от имени авторов. Резолюция экспертного совета 4861 по проблеме легочной артераильнйо гипертензии «Меняя парадигму лечения пациентов с 4862 ЛАГ». Терапевтический архив. 2019;91(3):114-116. 4863 193. Gaine S, Sitbon O, Channick RN, et al. Relationship Between Time From Diagnosis 4864 and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III 4865 GRIPHON Study. Chest. 2021; 160(1): 277–286. 4866 194. Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial 4867 hypertension: Insights from the GRIPHON study. J of Heart and lung Transplantation: the official 4868 publication of the International Society for Heart Transplantation 2020; 39(4): 300–309. 4869 195. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan 4870 in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694. 4871 196. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled 4872 iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 4873 2006;174:1257–1263. 4874 197. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse 4875 population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30:93–99. 4876 198. Thakrar MV, Weatherald JC, Varughese RA, et al. Initial Combination Therapy 4877 With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label 4878 Study. J Heart Lung Transplant. 2018;37(4S):S53-S54. 4879 199. Satoshi A, Yoshihiro D, Kaori I, et al. Effects of Dual Initial Combination Therapy 4880 With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With 4881 Pulmonary Arterial Hypertension (SETOUCHI-PH Study) - Protocol of a Multicenter 4882 Randomized Control Trial. Circ Rep. 2021;3(2):105-109. 4883 200. McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil 4884 therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405-13. 4885 201. Hoeper, MM, Al-Hiti, H, Benza, RL, et al. Switching to riociguat versus 4886 maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial 4887 hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet. 4888 Respiratory medicine. 2021; 9(6)573–584. 4889 202. Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in 4890 pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 4891 inhibitors. Eur Respir J. 2017; 50(3): 1602425. 4892 203. Taran IN, Belevskaya AA, Saidova MA, et al. Initial Riociguat Monotherapy and 4893 Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial 4894 Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial 4895 Coupling. Lung. 2018; 196(6):745-753. 204. Мартынюк Т.В., Шмальц А.А., Горбачевский С.В., Чазова И.Е. Оптимизация 4897 специфической терапии легочной гипертензии: возможности риоцигуата. Терапевтический 4898 архив. 2021; 93 (9): 1117–1124. 4899 205. Li J, Yang ZY, Wang S, et al. Efficacy and safety of switching from bosentan or 4900 ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta4901 analysis.Front Cardiovasc Med. 2022;9:977110. 4902 206. ???? 4903 207. Sandoval J, Gomez-Arroyo J, Gaspar J, Pulido-Zamudio T. Interventional and 4904 surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments. 4905 J Cardiol. 2015; 66(4):304-14. 4906 208. Gorbachevsky SV, Shmalts AA, Dadabaev GM, et al. Outcomes of 4907 Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large 4908 Single-Institution Cohort. Diagnostics (Basel). 2020;10(9):725. 4909 209. Горбачевский С.В., Пурсанов М.Г., Шмальц А.А., др. Результаты 4910 атриосептостомии со стентированием у больных с идиопатической и схожими формами 4911 легочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия. 2019; 61 (2): 4912 100-113. 4913 210. Шмальц А.А., Нишонов Н.А. Атриосептостомия у больных с легочной 4914 гипертензией. Грудная и сердечно-сосудистая хирургия. 2015; 57 (5): 18-25. 4915 211. Khan MS, Memon MM, Amin E, et al. Use of balloon atrial septostomy in patients 4916 with advanced pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 4917 2019; 156:53–63. 4918 212. Bartolome SD., Torres F. Severe pulmonary arterial hypertension: stratification of 4919 medical therapies, mechanical support, and lung transplantation. Heart Fail Rev. 2016; 21(3):347– 4920 356. 4921 213. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and 4922 lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019; 53: 1801906. 4923 214. Jentzer JC, Mathier, MA. Pulmonary Hypertension in the Intensive Care Unit. J 4924 Intensive Care Med. 2016; 31(6):369–385. 4925 215. Горбачевский С.В., Шмальц А.А., Плотникова Л.Р. Легочная гипертензия у 4926 детей с врожденными пороками сердца. М.: ООО «Кедр»; 2018. 4927 216. Барышникова И.Ю., Шмальц А.А. Диагностика легочной гипертензии, 4928 ассоциированной с врожденными пороками сердца. Часть 2. Эхокардиография. Российский 4929 вестник перинатологии и педиатрии. 2021; 66:(6): 23–32. 4930 217. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for 4931 the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. 4932 218. Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфические легочные 4933 вазодилататоры после операции Фонтена. Детские болезни сердца и сосудов. 2017; 14 (1): 4934 16-24. 4935 219. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a 4936 critical review. Pulm Circ 2020;10:2045894020917885. 4937 220. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with 4938 Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. 4939 Circulation 2006; 114:48–54. 4940 221. Шмальц А.А., Горбачевский С.В. Доказательная база специфических 4941 легочных вазодилататоров у взрослых с врожденными пороками сердца. Терапевтический 4942 архив. 2021; 93 (9): 1106-1116. 4943 222. Соболев А.В., Шмальц А.А. Эндоваскулярная диагностика легочной 4944 гипертензии, ассоциированной с врожденными пороками сердца. Часть 1. Катетеризация 4945 сердца и ангиокардиография. Эндоваскулярная хирургия. 2021; 8 (3): 263–71. 125 4946 223. Шмальц А.А., Нишонов Н.А. Эндоваскулярная диагностика легочной 4947 гипертензии, ассоциированной с врожденными пороками сердца. Часть 2. Расчет 4948 гемодинамики методом Фика. Эндоваскулярная хирургия. 2021; 8 (4): 339–46. 4949 224. Гусева, Н. Г. Системная склеродермия -мультидисциплинарная проблема. 4950 Научно-практическая ревматология. 2011; 49(2): 10-14. 4951 225. Волков А.В., Мартынюк Т.В., Юдкина Н.Н. и др. Выживаемость пациентов с 4952 легочной артериальной гипертонией, ассоциированной с системной склеродермией. 4953 Терапевтический архив. 2012; 84(5): 24-28. 4954 226. Rubio-Rivas M, Royo C, Simeón CP, et al.. Mortality and survival in systemic 4955 sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-19. 4956 227. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial 4957 hypertension registry. Eur Respir Rev. 2012;21(123):8-18. 4958 228. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: 4959 results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. 4960 229. Attanasio U, Cuomo A, Pirozzi F, et al. Pulmonary Hypertension Phenotypes in 4961 Systemic Sclerosis: The Right Diagnosis for the Right Treatment. Int J Mol Sci. 2020;21(12):4430. 4962 230. Николаева Е.В., Корсакова Ю.О., Курмуков И.А. и др. Возможности 4963 эхокардиографического определения давления в легочной артерии у пациентов с 4964 системными заболеваниями соединительной ткани: данные ревматологического 4965 экспертного центра. Научно-практическая ревматология. 2015; 53(1):51-57 4966 231. Юдкина Н.Н., Николаева Е.В., Мартынюк Т.В. и др. Клинический субтип 4967 системной склеродермии, ассоциированный с легочной артериальной гипертензией. 4968 Кардиологический вестник. 2017; 12(4): 66-75. 4969 232. Mularek-Kubzdela T, Ciurzyński M, Kowal Bielecka O, et al. An expert opinion of 4970 the Polish Cardiac Society Working Group on Pulmonary Circulation and the Polish Society for 4971 Rheumatology on the diagnosis and treatment of pulmonary hypertension in patients with 4972 connective tissue disease. Kardiol Pol. 2021;79(7-8):917-929. 4973 233. Simpson CE, Damico RL, Hummers L, et al. Serum uric acid as a marker of disease 4974 risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm 4975 Circ. 2019;9(3):2045894019859477. 4976 234. Santos-Gomes J, Gandra I, Adão R, et al. An Overview of Circulating Pulmonary 4977 Arterial Hypertension Biomarkers. Front Cardiovasc Med. 2022;9:924873. 4978 235. Simpson CE, Damico RL, Hummers L, et al. Serum uric acid as a marker of disease 4979 risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm 4980 Circ. 2019;9(3):2045894019859477. 4981 236. Hao Y, Thakkar V, Stevens W, et al. A comparison of the predictive accuracy of 4982 three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res 4983 Ther. 2015;17(1):7. 4984 237. Конева О.А., Овсянникова О.Б., М. Н. Старовойтова и др. Изолированное 4985 снижение диффузионной способности легких при системной склеродермии без легочной 4986 артериальной гипертензии: длительное проспективное наблюдение. Пульмонология. 2016; 4987 26(6):708-714. 4988 238. Xanthouli P. Improved Survival for Patients with Systemic Sclerosis-associated 4989 Pulmonary Arterial Hypertension: For Real? Am J Respir Crit Care Med. 2023;207(3):238-240. 4990 239. Bourji KI, Kelemen BW, Mathai SC, et al. Poor survival in patients with 4991 scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. 4992 Pulm Circ. 2017;7(2):409-420. 4993 240. Chauvelot L, Gamondes D, Berthiller J, et al. Hemodynamic Response to Treatment 4994 and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus 4995 Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic 4996 Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis 4997 Rheumatol. 2021;73(2):295-304. 126 4998 241. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in 4999 pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly 5000 Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65. 5001 242. Garry JD, Kolaitis NA, Kronmal R, et al. Pulmonary Hypertension Association 5002 Registry Investigators. Anticoagulation in pulmonary arterial hypertension - association with 5003 mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association 5004 Registry (PHAR). J Heart Lung Transplant. 2022;41(12):1808-1818. 5005 243. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from 5006 the US-based REVEAL Registry. Chest.2012;141:906–915. 5007 244. Baiges A, Turon F, Simon-Talero M, et al. Congenital extrahepatic portosystemic 5008 shunts (Abernethy malformation): an international observational study. Hepatology. 2020;71:658– 5009 669. 5010 245. Savale L, Guimas M, Ebstein N, Fertin M, et al. Portopulmonary hypertension in 5011 the current era of pulmonary hypertension management. J Hepatol 2020;73:130–139. 5012 246. Sitbon O, Bosch J, Cottrel E, et al. Macitentan for the treatment of portopulmonary 5013 hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 5014 trial. Lancet Respir Med. 2019;7(7):594-604. 5015 247. Lazaro SM, Quezada Loaiza CA, Rodriguez Padial L, et al. Portopulmonary 5016 hypertension: prognosis and management in the current treatment era - results from the REHAP 5017 registry. Intern Med J. 2021;51:355–365. 5018 248. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial 5019 hypertension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40. 5020 249. Ryom L, Cotter A, De Miguel R, et al. 2019 update of the European AIDS Clinical 5021 Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020;21:617– 5022 624. 5023 250. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human 5024 immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 5025 2004;170:1212–1217. 5026 251. Bermejo J, Gonzalez-Mansilla A, Mombiela T, et al. Persistent pulmonary 5027 hypertension in corrected valvular heart disease: hemodynamic insights and long-term survival. J 5028 Am Heart Assoc 2021;10: e019949. 5029 252. Hoeper MM, Meyer K, Rademacher J, et al. Diffusion capacity and mortality in 5030 patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC 5031 Heart Fail. 2016;4:441–449 5032 253. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the 5033 management of valvular heart disease. Eur Heart J. 2022;43:561–632. 5034 254. Crawford TC, Leary PJ, Fraser CD, et al. Impact of the new pulmonary 5035 hypertension definition on heart transplant outcomes: expanding the hemodynamic risk profile. 5036 Chest 2020;157:151–161 5037 255. Muraru D, Parati G, Badano L. The importance and the challenges of predicting the 5038 progression of functional tricuspid regurgitation. JACC Cardiovasc Imaging 2020;13:1652–1654. 5039 256. Andersen MJ, Hwang SJ, Kane GC, et al. Enhanced pulmonary vasodilator reserve 5040 and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection 5041 fraction. Circ Heart Fail.2015;8:542–550 5042 257. Cao JY, Wales KM, Cordina R, et al. Pulmonary vasodilator therapies are of no 5043 benefit in pulmonary hypertension due to left heart disease: A meta-analysis. Int J Cardiol 5044 2018;273:213–220. 5045 258. Алеевская А.М., Выборов О.Н., Грамович В.В., Мартынюк Т.В. Проблемные 5046 аспекты легочной гипертензии вследствие патологии левых отделов сердца: фокус на 5047 комбинированную пост/прекапиллярную форму. Терапевтический архив. 2020;92 (9): 54– 5048 62. 127 5049 259. D’Alto M, Romeo E, Argiento P, et al. Clinical relevance of fluid challenge in 5050 patients evaluated for pulmonary hypertension. Chest 2017;151:119–126. 5051 260. Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance 5052 predicts mortality in COPD patients. Eur Respir J 2021; 58: 2100944. 5053 261. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients 5054 with idiopathic pulmonary fibrosis. Chest. 2005; 128: 2393-2399. 5055 262. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes 5056 of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 5057 746–752. 5058 263. Zisman DA, Lynch JP, Strieter RM, et al. Pulmonary arterial hypertension (PAH) 5059 is common in patients with idiopathic pulmonary fibrosis referred for lung transplantation. Am J 5060 Respir Crit Care Med. 2005; 2: A123. 5061 264. Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts 5062 mortality in patients with pulmonary hypertension associated with interstitial lung disease: results 5063 from the COMPERA registry. Eur Respir J 2021; 58: 2101483. 5064 265. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, et al. Severe 5065 pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 5066 2005; 172: 189–194. 5067 266. Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al. 5068 Pulmonary hypertension in patients with COPD: results from COMPERA. Chest 2021; 160: 678– 5069 689. 5070 267. Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, et al. 5071 Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a 5072 prospective French multicenter cohort. J Heart Lung Transplant 2021; 40: 1009–1018. 5073 268. Kovacs G, Agusti A, Barbera JA, et al. Pulmonary vascular involvement in COPD 5074 - is there a pulmonary vascular phenotype? Am J Respir Crit Care Med 2018; 198: 1000–1011. 5075 269. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD 5076 candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531– 5077 1536. 5078 270. Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor 5079 treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian 5080 retrospective observational cohort study. Respirology. 2023; 28:262-72. 5081 271. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with 5082 ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158: 641–649. 5083 272. Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial 5084 pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled 5085 phase 2b study. Lancet Respir Med 2019; 7: 780–790. 5086 273. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary 5087 hypertension. Eur Respir J. 2019; 53(1). pii: 1801915. 5088 274. Валиева З.С., Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. 5089 Характеристика пациентов с хронической тромбоэмболической легочной гипертензией по 5090 данным российского национального регистра Терапевтический архив. 2021;93(9): 1058- 5091 1065. 5092 275. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the 5093 diagnosis and management of acute pulmonary embolism developed in collaboration with the 5094 European Respiratory Society (ERS).Eur Heart J. 2020;41:543–603. 5095 276. Swietlik EM, Ruggiero A, Fletcher AJ, et al. Limitations of resting haemodynamics 5096 in chronic thromboembolic disease without pulmonary hypertension. Eur Respir J 5097 2019;53:1801787. 5098 277. Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of 5099 cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. 5100 Int J Cardiol.2013;167:1193–1198. 128 5101 278. Badagliacca R, Rischard F, Giudice FL, et al. Incremental value of 5102 cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension. J Heart 5103 Lung Transplant. 2022;41:780–790. 5104 279. Симакова М.А., Злобина И.С., Березина А.В., др.. Эффективность лечения 5105 пациентов с хронической тромбоэмболической легочной гипертензией. Кардиология. 2022; 5106 62(4): 44-54. 5107 280. Helmersen D, Provencher S, Hirsch AM, et al. Diagnosis of chronic 5108 thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline 5109 update. Can J Respir Crit Care Sleep Med. 2019;3:177–198. 5110 281. Пищулов К.А., Симакова М.А., Карпова Д.В., Моисеева О.М. Использование 5111 компьютерной томографии в оценке степени тяжести пациентов с хронической 5112 тромбоэмболической легочной гипертензией. Артериальная гипертензия. 2021; 27(3):333- 5113 340. Симакова М.А., Гончарова Н.С., Карпова Д.В., др. Рекомендации по диагностике и 5114 лечению пациентов с легочной гипертензией в условиях пандемии covid-19. Артериальная 5115 гипертензия. 2020; 26(3): 343-355. 5116 282. Skoro-Sajer N, Marta G, Gerges C, et al. Surgical specimens, haemodynamics and 5117 long-term outcomes after pulmonary endarterectomy. Thorax. 2014; 69(2): 116–122. 5118 283. Jenkins DP, Biederman A, D"Armini AM, et al. Operability assessment in CTEPH: 5119 Lessons from the CHEST-1 study. J Thorac Cardiovasc Surg. 2016; 152(3):669–674. 5120 284. Чернявский А.М., Едемский А.Г., Новикова Н.В., др. Хирургическое лечение 5121 хронической тромбоэмболической легочной гипертензии./ Национальный медицинский 5122 исследовательский центр имени Е. Н. Мешалкина; под общей редакцией А. М. Чернявского. 5123 — Новосибирск : НМИЦ : Издательство СО РАН, 2019. — 317 с. 5124 285. Araszkiewicz A, Darocha S, Pietrasik A, et al. Balloon pulmonary angioplasty for 5125 the treatment of residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int 5126 J Cardiol. 2019;278: 232–237. 5127 286. Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Баллонная ангиопластика легочных 5128 артерий при неоперабельной хронической тромбоэмболической легочной гипертензии. 5129 Сonsilium Medicum. 2016; 5: 59-61. 5130 287. Марукян Н.В., Симакова М.А., Зубарев Д.Д., Моисеева О.М. Принципы 5131 выбора лечебной стратегии у пациентов с неоперабельной формой хронической 5132 тромбоэмболической легочной гипертензии. Рациональная фармакотерапия в кардиологии. 5133 2021;17(2):278-285. 5134 288. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent 5135 changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 5136 2012;94:97–103. 5137 289. Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic 5138 thromboembolic pulmonary hypertension. J Heart Lung Transplant 2018;37:250–258. 5139 290. Акчурин Р.С., Мершин К.В., Табакьян Е.А., др. Хирургическое лечение 5140 хронической тромбоэмболической легочной гипертензии: современные тенденции и 5141 собственный опыт. Евразийский Кардиологический Журнал. 2016; 2:40-47. 5142 291. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al. 5143 Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac 5144 Cardiovasc Surg 2014;148:1005–1011. 5145 292. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary 5146 endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014;44:1635– 5147 1645. 5148 293. Newnham M, Bunclark K, Abraham N, et al. CAMPHOR score: patient-reported 5149 outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary 5150 hypertension. Eur Respir J. 2020;56:1902096. 294. Чернявский А.М., Едемский А.Г., Чернявский М.А., др. Пятилетние 5152 результаты хирургического лечения пациентов с хронической постэмболической легочной 5153 гипертензией Хирургия. Журнал им. Н.И. Пирогова. 2017; 2: 21-24. 5154 295. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary 5155 endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014; 44:1635– 5156 1645. 5157 296. Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival 5158 in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018;52:1800589. 5159 297. Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of 5160 chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319–329. 5161 298. Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat 5162 for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a 5163 multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet 5164 Respir Med. 2022; 10(10):961-971. 5165 299. Delcroix M, Staehler G, Gall H, et al. Risk assessment in medically treated chronic 5166 thromboembolic pulmonary hypertension patients. Eur Respir J. 2018;52:1800248. 5167 300. Benza RL, Farber HW, Frost A, Grunig E, Hoeper MM, Busse D, et al. REVEAL 5168 risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. J 5169 Heart Lung Transplant. 2018;37:836–843. 5170 301. Humbert M, Farber HW, Ghofrani HA, et al. Risk assessment in pulmonary arterial 5171 hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J. 5172 2019;53:1802004. 5173 302. Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation 5174 in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020;18:114– 5175 122. 5176 303. Humbert MS, Simonneau G, Pittrow D, et al. Oral anticoagulants (NOAC and 5177 VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 5178 2022;41:716–721. 5179 304. Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Rivaroxaban versus vitamin K 5180 antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 5181 2019;171: 685–694. 5182 305. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk 5183 patients with antiphospholipid syndrome. Blood. 2018;132: 1365–1371. 5184 306. Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of 5185 inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the 5186 multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 5187 2017;5:785–794. 5188 307. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary 5189 endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 5190 2010;139:85–91. 5191 308. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil 5192 in chronic thromboembolic pulmonary hyper- tension. Eur Respir J. 2007;30:922–927 5193 309. Wiedenroth CB, Ghofrani HA, Adameit MSD, et al. Sequential treatment with 5194 riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic 5195 pulmonary hypertension. Pulm Circ. 2018; 8:2045894018783996. 5196 310. Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon 5197 pulmonary angioplasty. Eur Respir J. 2014; 43:1394–1402. 5198 311. Darocha S, Pietura R, Pietrasik A, et al. Improvement in quality of life and 5199 hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon 5200 pulmonary angioplasty. Circ J 2017;81: 552–557. 5201 312. Lang I, Meyer BC, Ogo T, et al. Balloon pulmonary angioplasty in chronic 5202 thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26:160119. 130 5203 313. Mahmud E, Behnamfar O, Ang L,et al. Balloon pulmonary angioplasty for chronic 5204 thromboembolic pulmonary hypertension. Interv Cardiol Clin. 2018;7:103–117. 5205 314. Ogawa A, Matsubara H. After the dawn-balloon pulmonary angioplasty for patients 5206 with chronic thromboembolic pulmonary hypertension. Circ J 2018; 82:1222–1230. 5207 315. Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, et al. Balloon 5208 pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a 5209 multicenter registry. Circ Cardiovasc Qual Outcomes. 2017;10: e004029. 5210 316. Данилов Н.М., Матчин Ю.Г., Чернявский А.М., др. Транслюминальная 5211 баллонная ангиопластика легочных артерий у больных с неоперабельной хронической 5212 тромбоэмболической легочной гипертензией. Терапевтический архив. 2019; 91(4):43-47. 5213 317. Марукян Н.В., Симакова М.А., Карпова Д.В., др. Реперфузионный отек 5214 легкого как осложнение баллонной ангиопластики легочной артерии у пациентов с 5215 хронической тромбоэмболической легочной гипертензией. Флебология. 2017; 11(4): 243– 5216 248. 5217 318. Аржанцев А.С., Данилов Н.М., Атанесян Р.В., др. Перфорация легочных 5218 артерий при проведении транслюминальной баллонной ангиопластики Кардиологический 5219 вестник. 2021; 16(1):56-63. 5220 319. Данилов Н.М., Яровой С.Ю., Елфимова Е.М., др. Клинические и 5221 рентгенологические аспекты реперфузионного отёка лёгких после транслюминальной 5222 баллонной ангиопластики лёгочных артерий у пациентов с хронической 5223 тромбоэмболической лёгочной гипертензией. Системные гипертензии. 2022; 19(3): 23-30. 5224 320. Brenot P, Jais X, Taniguchi Y, et al. French experience of balloon pulmonary 5225 angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802095. 5226 321. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive 5227 medical therapy in chronic thromboembolic pulmonary hypertension before 5228 pulmonary thromboendarterectomy. Circulation. 2009;120(13):1248-54. 5229 DOI:10.1161/CIRCULATIONAHA.109.865881 5230 322. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 5231 2018. Национальные рекомендации. Российский кардиологический журнал 2018, 3 (155): 5232 91–134. 5233 323. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines 5234 for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39: 3165– 5235 3241. 5236 324. Hill W., Holy R., Traiger G. EXPRESS: Intimacy, Contraception, and Pregnancy 5237 Prevention in Patients with Pulmonary Arterial Hypertension: Are We Counseling Our Patients? 5238 Pulm Circ. 2018;10(4):2045894018785259.Olsson KM, Channick R. Pregnancy in pulmonary 5239 arterial hypertension. Eur Respir Rev. 2016; 25: 431–437. 5240 325. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol 5241 Endocrinol 2013; 29:1–14. 5242 326. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary 5243 hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015; 5: 435–465. 5244 327. Roos-Hesselink JW, Budts W, Walker F, et al. Organisation of care for pregnancy 5245 in patients with congenital heart disease. Heart. 2017; 103:1854–1859. 5246 328. Hsu CH, Gomberg-Maitland M, Glassner C, et al. The management of pregnancy 5247 and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin 5248 Pract Suppl. 2011; 175: 6–14. 5249 329. Terek D, Kayikcioglu M, Kultursay H, et al. Pulmonary arterial hypertension and 5250 pregnancy. J Res Med Sci. 2013; 18: 73–76. 5251 5252 5253 5254 131